Cholestech Announces European Patent Grant on HDL-Cholesterol Assay for Use on the Cholestech L-D-X System.Business Editors/Health & Medical Writers HAYWARD, Calif.--(BW HealthWire)--March 7, 2001 Patent Increases Confidence in the Cholestech LDX LDX Load X (6502 processor instruction) LDX Long Distance Extender LDX Long-Distance Xerox LDX Low Density Line LDX Load Index in the European Market Cholestech Corporation (Nasdaq:CTEC CTEC Course and Teacher Evaluation Council (Northwestern University, Office of the Register) CTEC Certified Technical Education Center CTEC Certified Technical Education Center (Microsoft) ) today announced that the European Patent Office has granted European patent number EP 0 539 495 for the company's High Density Lipoprotein High density lipoprotein (HDL) A fraction of total serum lipids, the so called "good" cholesterol. Mentioned in: Hypercholesterolemia (HDL (Hardware Description Language) A language used to describe the functions of an electronic circuit for documentation, simulation or logic synthesis (or all three). Although many proprietary HDLs have been developed, Verilog and VHDL are the major standards. ) cholesterol assay for use on the Cholestech LDX. Published on January 17, 2001, the grant gives Cholestech patent rights in Austria, Belgium, Switzerland, Germany, France, Spain, Great Britain, Italy, Luxembourg and the Netherlands. Under German patent law, opposition against the patent is possible, and the nationalization nationalization, acquisition and operation by a country of business enterprises formerly owned and operated by private individuals or corporations. State or local authorities have traditionally taken private property for such public purposes as the construction of of the patent in several countries is only initiated. Cholestech has reported international sales of $4.1 million year-to-date, or 15.5 percent of revenue, with approximately 80 percent of international sales coming from the European market. Cholestech empowers people with the tools and information to help assess, manage and improve their health in order to lead longer, healthier and more active lives. "The ability to conduct panels of cholesterol tests which include HDL is a key differentiator for Cholestech in the European market", said Robert J. Dominici, chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of Cholestech's Diagnostic Products business. "Three quarters of our international business comes from cholesterol tests which include HDL. International customers have been quick to adopt Cholestech's innovative, near-patient technology, resulting in 42 percent sales growth in our international markets year-to-date." The HDL cholesterol HDL cholesterol n. See high-density lipoprotein. HDL Cholesterol About one-third or one-fourth of all cholesterol is high-density lipoprotein cholesterol. test measures the amount of "good" cholesterol in the blood of a patient. This test, when combined with the other tests in a Lipid Profile lipid profile, n a series of tests used to gauge a person's risk for coro-nary heart conditions. Blood levels examined in a lipid profile include those for total cholesterol, LDL- and HDL-cholesterol, and triglycerides. , helps determine the ratio of HDL to LDL cholesterol LDL cholesterol n. See low-density lipoprotein. LDL Cholesterol Low-density lipoprotein cholesterol is the primary cholesterol molecule. High levels of LDL increase the risk of coronary heart disease. . LDL cholesterol, or Low Density Lipoprotein Low density lipoprotein (LDL) A fraction of total serum lipids, the so called "bad" cholesterol. Mentioned in: Hypercholesterolemia , is often referred to as the "bad" cholesterol. HDL/LDL ratios can be used to help determine an individual's risk of coronary heart disease coronary heart disease: see coronary artery disease. coronary heart disease or ischemic heart disease Progressive reduction of blood supply to the heart muscle due to narrowing or blocking of a coronary artery (see atherosclerosis). . The Cholestech L-D-X System can conduct multiple simultaneous diagnostic tests from a single drop of blood and provide results, in less than five minutes, which are as accurate as similar tests performed in clinical and hospital labs. About Cholestech Cholestech is committed to helping people successfully improve their health. Working together, the Cholestech business units of Diagnostic Products, WellCheck(TM), and WellCheck.com can provide simple, accessible, and reliable personal health information to health care practitioners and consumers in over 35 countries around the world. By offering efficient and economic diagnostic screening for cholesterol, blood sugar, and liver function, Cholestech hopes to help more people understand whether or not they face potentially serious health risks. Therapeutic monitoring options using the Cholestech L-D-X System can help patients monitor their progress as they work with their health care provider to reduce their risk of cardiovascular and other diseases. Working together with health care providers, our goal is to ultimately enable people to lead longer, healthier, and more active lives. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement of Cholestech Corporation under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This release contains forward-looking statements as defined in the Private Securities Litigations Reform Act of 1995 regarding: anticipated consumer response to Cholestech products and services and the acceptance of Cholestech technology by the medical community, or specific regulating bodies. Actual results may differ materially from those in the forward-looking statements due to risks and uncertainties, including: our inability to accurately predict levels of consumer interest in cholesterol testing and personal health management; changing relationships with customers, suppliers, sponsors and strategic partners; potential contractual, intellectual property, or employment issues; lack of significant experience in managing geographically diverse operations; Cholestech has in the past experienced, and may in the future experience significant fluctuations in revenues and results of operations on a quarter to quarter basis; and other factors. These and other risks are detailed from time to time in Cholestech's periodic reports filed with the Securities Exchange Commission, including, but not limited to, our report on Form 10-K for our fiscal year ended March 31, 2000 and our report on Form 10-Q for our fiscal quarter ended December 29, 2000, particularly those factors mentioned in the sections captioned "Managements Discussion and Analysis of Financial Condition and Results of Operations -- Potential Factors Affecting Future Operating Results". Note to Editors: Cholestech L-D-X, WellCheck(TM), and WellCheck.com are registered trademarks of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products visit us on the web at www.cholestech.com WellCheck.com is available to the general public at www.wellcheck.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion